发布于: 雪球转发:0回复:0喜欢:0
回复@1780杰森: 如果是这样,今天A股的cxo大跌很奇怪,另外,TT上演法律攻防,药明受如此莫须有的待遇,如果定案的是很不利的版本,有没有法律攻防的选项?//@1780杰森:回复@世方游:The bipartisan legislation would prohibit federal contracts, loans or grants to any Chinese “biotechnology company of concern.” That would apply to companies with research agreements with the National Institutes of Health or sales to the Department of Veterans Affairs or the Department of Defense, including TRICARE.
Because reimbursements are not considered a federal contract, the updated legislation would not affect Medicare and Medicaid payments, according to staff on the 网页链接{House Oversight and Accountability Committee}, which will be voting on the bill.
引用:
2024-05-15 10:26
[加]在不起动融资情况下,我还有近60万元美元可加仓。希望用在中金公司与微创医疗上,药明生物就别来分一杯羹啦。近60万美元基本不够应付3档股票。
[红包]微创医疗只剩下30万股,股数大部分是今年初那波上涨赚来的,成本低廉至可以忽略掉。
[太阳]药明生物今晚投票结果揭晓,愿市场主力来...